Almac Group scoops R&D Achievement at 2018 Irish Pharma Industry Awards
25th October 2018
Following the success of picking up last year’s ‘Export Achievement’ award, Almac Group, the global contract development and manufacturing organisation, is delighted to announce it has won the Research & Development Achievement Award during this year’s Irish Pharma Industry Award ceremony. This award recognises the company’s commitment to delivering the highest quality R&D services to its global clients.
An independent panel, which comprised 14 industry leaders, judged the entries and determined the winners based on a number of key attributes. Almac’s entry was selected as the winner due to its highly effective and innovative selectAZyme™ research programme which offers green, economic, robust, scaleable and reliable processes for synthesis of chiral APIs and intermediates. It was one of 24 awards presented during the event.
“We are honoured to receive the Research and Development award which once again showcases the successful integration of the diverse and highly skilled technical workforce of Almac and Arran.” Commented Dr Stephen Barr, Managing Director, Almac Sciences. “This award serves to highlight our team’s dedication and commitment to quality and also showcases our ability to solve complex technical challenges. We’re grateful for this award and look forward to drive further success with our continued focus on a range of R&D programmes.”
Since launching in 2014, the Pharma Industry Awards recognise the successes and achievements of Ireland’s pharmaceutical industry and are seen as the benchmark for excellence for those operating within the sector. The winners were revealed at a Gala Awards dinner on 23rd October at The Clayton Hotel, Dublin.
Additionally, Almac Clinical Services’ team was a shortlist-nominee for the Supply Chain Achievement Award, which spotlighted their success with having extensive global coverage and expertise in servicing end-to-end supply chain management.
The Pharma Industry Awards celebrates individuals and companies who most distinguish themselves and demonstrate a commitment to innovative solutions and exemplary quality in the Irish Pharma sector. Ranging from process and formulation to contract-development and manufacturing services, these awards allow recipients to showcase their strengths and annual investments. Almac last received the R&D achievement award in 2014 for it work on Almac Diagnostic Services’ proprietary DNA Damage Repair Deficiency (DDRD) test which helps predict which breast cancer patients are likely to benefit from chemotherapy based on their genetic make-up.